EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis
about
Circulating tumor cells isolation: the "post-EpCAM era"EpCAM in carcinogenesis: the good, the bad or the uglyRegulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signalingNuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.Protein mislocalization: mechanisms, functions and clinical applications in cancer.Chemotherapy enhances cross-presentation of nuclear tumor antigensNuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.High EpCAM expression is linked to proliferation and lauren classification in gastric cancer.Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomasCoexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinomaSubcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosisUsing aptamers to elucidate esophageal cancer clinical samplesEpithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer.Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences.EpCAM-Regulated Transcription Exerts Influences on Nanomechanical Properties of Endometrial Cancer Cells That Promote Epithelial-to-Mesenchymal Transition.Epithelial cell adhesion molecule-positive human hepatic neoplastic cells: development of combined hepatocellular-cholangiocarcinoma in mice.MMP7 is a target of the tumour-associated antigen EpCAM.Association of Cancer Stem Cell Markers With Aggressive Tumor Features in Papillary Thyroid Carcinoma.Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells.EpCAM proteolysis: new fragments with distinct functions?Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.A high-content screen for small-molecule regulators of epithelial cell-adhesion molecule (EpCAM) cleavage yields a robust inhibitor.Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
P2860
Q26778917-6CC90B71-FD49-422D-89B4-BAFF62C939D8Q28293163-F85B94A8-DCAB-429C-A3EA-369F707FFDD9Q28586334-A32AC7E9-0B96-45C3-93E2-AB94F158B99FQ33770286-D4645E85-C81C-453A-A7B9-311F7BDFE534Q34076405-344C7D06-585C-46CD-A8EA-1432D050FE43Q34226903-4EBF5222-A260-4771-9F26-29C4B5DC27D8Q34308781-0AEC5376-3A81-47DF-9EB0-F1A8FF7E9B2CQ34387562-942234AB-AB25-4CED-94F7-9B99E4D5189EQ34437810-C182C029-F732-4218-8038-CD90349CF253Q34478477-36D1C67E-60DC-404C-901B-0105D81B4B55Q34570056-E29084D5-88A3-4441-B363-0F468254299FQ34800662-716DA29D-349B-4235-B211-7035914BE300Q35103343-1439974D-D613-4E75-B7A7-6B5B7E4BCB38Q35146510-20840C7E-2714-40EB-8E7C-8C0EDCC5B817Q36078946-7EB89A6E-FDB7-4ED1-BF64-30D0C10AD1A5Q36387782-63C45BCF-214C-4DDF-A451-987C5CE85AB9Q36407948-38D5EEFC-2528-4018-B37A-A3407527ECC7Q36663666-AD29ECF6-F2C5-4F4D-8465-0DF82E883B4DQ37716015-1C438BE2-C850-49AC-8567-4783652DD17EQ38237908-1E4114A0-B413-4484-BBF7-606D649FD704Q38734383-13414BEA-C034-4BED-8694-49B541230328Q38969232-4336E269-9DE1-40AC-9DFD-C370FEE2B3D4Q39279697-830BF119-A837-4863-8C27-0A190C0CE5F8Q40200224-1778B5C0-FE54-48A3-8C8F-0D890DEA6BB9Q40842917-6FD985F6-3B67-42CC-A25F-6D433F3C7F91Q41458695-087E5871-E45F-4EB2-AA21-8D2E1E3BAD81Q43185053-67AC72B1-6197-4768-AA57-5291285AFEE5Q45849410-75B49C39-97F3-40AD-A198-579515C0654CQ47134733-2E1EB5E7-1E13-44CB-BFAE-52AA0557EE04Q52716409-7561E9D8-892E-4AB2-B1FB-991F66FACC33Q54777332-172DD853-E3AC-4057-BDC2-F6CD8303E1B4
P2860
EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@ast
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@en
type
label
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@ast
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@en
prefLabel
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@ast
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@en
P2093
P2860
P356
P1433
P1476
EpCAM nuclear localization ide ...... is a marker for poor prognosis
@en
P2093
Christina Macmillan
Jeremy L Freeman
Paul G Walfish
Ranju Ralhan
Terence Lim
P2860
P2888
P356
10.1186/1471-2407-10-331
P407
P577
2010-06-25T00:00:00Z
P5875
P6179
1028845556